Abstract: Bone marrow aspirate concentrate (BMAC) is a quick, minimally invasive, point-of-care therapy for equine orthopaedic injuries. Despite growing clinical use, standardised manufacturing methods are lacking, and the final product remains poorly characterised. Objective: To develop a reproducible protocol for equine BMAC production that yields predictable cellular and cytokine compositions. Methods: In vitro analytical study. Methods: Bone marrow aspirate (BMA) was harvested from the sternum of eight healthy adult horses and filtered to remove possible bony spicules. After centrifugation at 1000 × g for 10 min, the buffy coat was collected to generate BMAC. Cellular composition was assessed using standard haematology and cytology, and cytokine concentrations were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits. Data are presented as mean ± standard deviation. Results: BMA filtration successfully removed potential bony material without significantly altering the cellular profile. Cells were predictably concentrated in BMAC: total nucleated cells increased from 77 ± 30 × 10/μL to 240 ± 57 × 10/μL; and platelets from 119 ± 34 × 10/μL to 269 ± 81 × 10/μL. Anti-inflammatory cytokines were increased in BMAC: IL-1ra increased from 18,611.3 ± 5509.1 to 36,598.8 ± 5971.8 pg/mL; IL-10 from 9.0 ± 7.5 to 19.1 ± 15.6 ng/mL; and TGF-β1 from 2535.0 ± 3018.7 to 5073.8 ± 2175.9 pg/mL. Of the pro-inflammatory cytokines measured, only IL-1β was increased (287.5 ± 22.5 to 475.1 ± 206.0 pg/mL), while TNF-α and IL-6 were unchanged. Conclusions: The small cohort size (n = 8) limited sensitivity for detecting minor effects. The cytokine panel, while representative, does not encompass all potential bioactive mediators, and single-time-point measurements do not necessarily reflect in vivo release kinetics. The clinical efficacy of BMAC was not evaluated, preventing direct correlation between compositional features and therapeutic outcomes. Conclusions: The BMAC protocol yielded consistently concentrated nucleated cells, preserved cellular morphology, and enhanced the anti-inflammatory cytokine profile relative to post-filtration BMA. These findings provide a biological rationale for intra-articular and intra-lesional use of BMAC in equine patients.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
Overview
This study developed and validated a reproducible protocol for producing equine bone marrow aspirate concentrate (BMAC) with consistent cellular and cytokine compositions.
The research showed that the protocol effectively concentrates nucleated cells and increases anti-inflammatory cytokines, supporting the potential therapeutic use of BMAC for horse orthopedic injuries.
Background and Objective
Bone marrow aspirate concentrate (BMAC) is increasingly used as a point-of-care treatment for equine orthopedic injuries because it is quick and minimally invasive.
Despite its growing use, there is no standardized, well-characterized method to prepare BMAC, limiting understanding of its composition and effectiveness.
The study aimed to establish a reproducible protocol to produce BMAC from equine bone marrow that yields predictable cellular and cytokine profiles, which are important for therapeutic efficacy.
Methods
Sample collection: Bone marrow aspirate (BMA) was obtained from the sternum of eight healthy adult horses.
Filtration process: The BMA was filtered to remove bony spicules, which are small bone fragments that could interfere with downstream processing.
Centrifugation: The filtered BMA was centrifuged at 1000 × g for 10 minutes to separate components; the buffy coat layer was collected to create the BMAC.
Analysis:
Cellular components were measured using standard hematology and cytology techniques to identify total nucleated cells and platelets.
Cytokine levels, which play roles in inflammation and healing, were quantified with enzyme-linked immunosorbent assay (ELISA) kits for both anti-inflammatory and pro-inflammatory cytokines.
Data were summarized as mean ± standard deviation.
Results
Filtration outcome: Successfully removed bony fragments without significantly changing the cellular profile of the aspirate.
Cellular concentration:
Total nucleated cells increased significantly from 77 ± 30 × 10/μL in filtered BMA to 240 ± 57 × 10/μL in BMAC.
Platelets increased from 119 ± 34 × 10/μL to 269 ± 81 × 10/μL.
IL-1 receptor antagonist (IL-1ra) rose from 18,611.3 ± 5509.1 to 36,598.8 ± 5971.8 pg/mL.
Interleukin-10 (IL-10) increased from 9.0 ± 7.5 to 19.1 ± 15.6 ng/mL.
Transforming growth factor-beta 1 (TGF-β1) increased from 2535.0 ± 3018.7 to 5073.8 ± 2175.9 pg/mL.
Among pro-inflammatory cytokines:
Interleukin-1 beta (IL-1β) increased from 287.5 ± 22.5 to 475.1 ± 206.0 pg/mL.
Tumor necrosis factor-alpha (TNF-α) and Interleukin-6 (IL-6) levels remained unchanged.
Limitations
The sample size was small (eight horses), limiting the ability to detect subtle effects and variability between individuals.
The cytokine panel tested was not exhaustive, so other relevant bioactive molecules might have been missed.
Measurements were taken at a single time point, which may not reflect the dynamics of cytokine release in living tissue over time.
The study did not assess the clinical efficacy or healing outcomes after BMAC treatment, so direct links between composition and therapeutic benefit remain unclear.
Conclusions and Implications
The developed protocol reproducibly concentrates nucleated cells and platelets without damaging cell morphology.
The process enhances anti-inflammatory cytokines, which could contribute to the healing environment in orthopedic injuries.
The increase in IL-1β, a pro-inflammatory cytokine, might play a complex role in tissue healing, though further study is needed.
This biological characterization supports the rationale for using BMAC intra-articularly (within joints) or intra-lesionally (within injury sites) in equine patients.
Future studies should include clinical trials to correlate these cellular and cytokine profiles with treatment outcomes in horses.
Cite This Article
APA
Branning M, Gordon J, Schlemmer SN, Peroni JF.
(2026).
An equine bone marrow aspirate concentrate protocol yields a predictable cellular and cytokine profile.
Equine Vet J.
https://doi.org/10.1002/evj.70353
Department of Large Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Gordon, Julie
Department of Large Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Schlemmer, Samantha N
Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Peroni, John F
Department of Large Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
References
This article includes 44 references
Costa FR, Pires L, Martins RA, Santos M, Santos GS, Lana JV. Orthobiologics revisited: a concise perspective on regenerative orthopedics. Curr Issues Mol Biol 2025;47:247.
Hauser RA, Orlofsky A. Regenerative injection therapy with whole bone marrow aspirate for degenerative joint disease: a case series. Clin Med Insights Arthritis Musculoskelet Disord 2013;6:65–72.
Schafer R, DeBaun MR, Fleck E, Centeno CJ, Kraft D, Leibacher J. Quantitation of progenitor cell populations and growth factors after bone marrow aspirate concentration. J Transl Med 2019;17:115.
Cassano JM, Kennedy JG, Ross KA, Fraser EJ, Goodale MB, Fortier LA. Bone marrow concentrate and platelet‐rich plasma differ in cell distribution and interleukin 1 receptor antagonist protein concentration. Knee Surg Sports Traumatol Arthrosc 2018;26:333–342.
Dragoo JL, Guzman RA. Evaluation of the consistency and composition of commercially available bone marrow aspirate concentrate systems. Orthop J Sports Med 2020;8:2325967119893634.
Hegde V, Shonuga O, Ellis S, Fragomen A, Kennedy J, Kudryashov V. A prospective comparison of 3 approved systems for autologous bone marrow concentration demonstrated nonequivalency in progenitor cell number and concentration. J Orthop Trauma 2014;28:591–598.
Gaul F, Bugbee WD, Hoenecke HR Jr, D'Lima DD. A review of commercially available point‐of‐care devices to concentrate bone marrow for the treatment of osteoarthritis and focal cartilage lesions. Cartilage 2019;10:387–394.
Chandrashekar S, Jeyaraman M, Mounissamy P, Jeyaraman N, Khanna M, Gupta A. Safety and efficacy of bone‐marrow aspirate concentrate in hip osteoarthritis: a systematic review of current clinical evidence.. Indian J Orthop 2024;58:835–844.
Cohn RM, Schwarzkopf R, Jaffe F. Heterotopic ossification after total hip arthroplasty.. Am J Orthop (Belle Mead NJ) 2011;40:E232–E235.
Shields JS, Mofidi A, Ward WG, Jinnah RH. Does a plastic drape reduce incidence of heterotopic ossification after hip resurfacing?. Clin Orthop Relat Res 2011;469:1606–1613.
Kantak AP, Shah NN. Extensive surgical wound lavage reduces the incidence and severity of heterotopic ossification in primary total hip replacement: a study of 175 hip replacements.. Hip Pelvis 2017;29:234–239.
Commins J, Irwin R, Matuska A, Goodale M, Delco M, Fortier L. Biological mechanisms for cartilage repair using a BioCartilage scaffold: cellular adhesion/migration and bioactive proteins.. Cartilage 2021;13:984S–992S.
Belk JW, Lim JJ, Keeter C, McCulloch PC, Houck DA, McCarty EC. Patients with knee osteoarthritis who receive platelet‐rich plasma or bone marrow aspirate concentrate injections have better outcomes than patients who receive hyaluronic acid: systematic review and meta‐analysis.. Arthroscopy 2023;39:1714–1734.
Han JH, Jung M, Chung K, Jung SH, Choi CH, Kim SH. Bone marrow aspirate concentrate injections for the treatment of knee osteoarthritis: a systematic review of randomized controlled trials.. Orthop J Sports Med 2024;12:23259671241296555.
O'Farrell AM, Liu Y, Moore KW, Mui ALF. IL‐10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3‐dependent and ‐independent pathways.. EMBO J 1998;17:1006–1018.
Imam MA, Holton J, Ernstbrunner L, Pepke W, Grubhofer F, Narvani A. A systematic review of the clinical applications and complications of bone marrow aspirate concentrate in management of bone defects and nonunions.. Int Orthop 2017;41:2213–2220.
Imam MA, Holton J, Horriat S, Negida AS, Grubhofer F, Gupta R. A systematic review of the concept and clinical applications of bone marrow aspirate concentrate in tendon pathology.. SICOT J 2017;3:58.
Lin YC, Chen YJ, Fan TY, Chou PH, Lu CC. Effect of bone marrow aspiration concentrate and platelet‐rich plasma combination in anterior cruciate ligament reconstruction: a randomized, prospective, double‐blinded study.. J Orthop Surg Res 2024;19:4.
Muench LN, Kia C, Berthold DP, Uyeki C, Otto A, Cote MP. Preliminary clinical outcomes following biologic augmentation of arthroscopic rotator cuff repair using subacromial bursa, concentrated bone marrow aspirate, and platelet‐rich plasma.. Arthrosc Sports Med Rehabil 2020;2:e803–e813.
Lee DH, Ryu KJ, Kim JW, Kang KC, Choi YR. Bone marrow aspirate concentrate and platelet‐rich plasma enhanced bone healing in distraction osteogenesis of the tibia.. Clin Orthop Relat Res 2014;472:3789–3797.
Gigante A, Cecconi S, Calcagno S, Busilacchi A, Enea D. Arthroscopic knee cartilage repair with covered microfracture and bone marrow concentrate.. Arthrosc Tech 2012;1:e175–e180.
Gigante A, Calcagno S, Cecconi S, Ramazzotti D, Manzotti S, Enea D. Use of collagen scaffold and autologous bone marrow concentrate as a one‐step cartilage repair in the knee: histological results of second‐look biopsies at 1 year follow‐up.. Int J Immunopathol Pharmacol 2011;24:69–72.
Barot D, Usimaki A, Linardi RL, Arensberg CM, Ortved KF. Equine autologous blood‐based products contain variable quantities of transforming growth factor‐beta1, interleukin‐1 receptor antagonist, and alpha2‐macroglobulin.. Am J Vet Res 2025;86:ajvr.24.11.0363.
Ziegler CG, Van Sloun R, Gonzalez S, Whitney KE, DePhillipo NN, Kennedy MI. Characterization of growth factors, cytokines, and chemokines in bone marrow concentrate and platelet‐rich plasma: a prospective analysis.. Am J Sports Med 2019;47:2174–2187.
Sugaya H, Yoshioka T, Kato T, Taniguchi Y, Kumagai H, Hyodo K. Comparative analysis of cellular and growth factor composition in bone marrow aspirate concentrate and platelet‐rich plasma.. Bone Marrow Res 2018;2018:1549826.